Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: An overview of 3 randomized controlled trials

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Reich, Kristian [2 ]
Drew, Janice [3 ]
Peterson, Luke [4 ]
Lebwohl, Mark [5 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dermatologikum Hamburg & SCIderm Res Inst, Hamburg, Germany
[3] Dermira Inc, Menlo Pk, CA USA
[4] UCB Pharma, Raleigh, NC USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
3120
引用
收藏
页码：AB239 / AB239
页数：1
相关论文
共 50 条
  • [21] Incidence of infections in clinical trials of tildrakizumab for moderate-to-severe chronic plaque psoriasis
    Crowley, Jeffrey
    Leonardi, Craig
    Sturgill-Koszycki, Sheila
    Menter, Alan
    Mendelsohn, Alan M.
    Li, Qing
    Cichanowitz, Nicole
    Gree, Stuart
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB166 - AB166
  • [22] Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
    Soriano, Enrique R.
    Dellepiane, Analia
    Salvatierra, Gabriela
    Alejandro Benitez, Cristian
    Garcia Salinas, Rodrigo
    Baruzzo, Carlos
    FUTURE SCIENCE OA, 2018, 4 (04):
  • [23] Response in the placebo group in randomized controlled trials for moderate-to-severe psoriasis
    Afach, S.
    Le Cleach, L.
    Sbidian, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 15 - 15
  • [24] Advances in the treatment of moderate-to-severe plaque psoriasis
    Herrier, Richard N.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (09) : 795 - 806
  • [25] Guselkumab for the treatment of moderate-to-severe plaque psoriasis
    Yang, Eric J.
    Sanchez, Isabelle M.
    Beck, Kristen
    Sekhon, Sahil
    Wu, Jashin J.
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 333 - 344
  • [26] Guselkumab in the treatment of moderate-to-severe plaque psoriasis
    Lopez-Sanchez, Cristina
    Puig, Lluis
    IMMUNOTHERAPY, 2020, 12 (06) : 355 - 371
  • [27] Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A meta-analysis of randomized clinical trials
    Tao, Xing-Bao
    Huang, Yin-Qiu
    Zhou, Yi-Hong
    Zhang, Lv-Lang
    Chen, Yao-Kai
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (02) : 433 - 440
  • [28] Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials
    Gold, Linda Stein
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Pariser, David M.
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    Ramakrishna, Tage
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 287 - 293
  • [29] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 37 - 37
  • [30] Safety of tildrakizumab for moderate-to-severe chronic plaque psoriasis: Pooled analysis of three randomized controlled studies
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Kimball, Alexa B.
    Gooderham, Melinda
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Li, Qing
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB252 - AB252
12345